These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

494 related articles for article (PubMed ID: 31352645)

  • 1. A case of esophageal cancer with human immunodeficiency virus infection that progressed rapidly after neoadjuvant chemoradiotherapy.
    Hayakawa Y; Kobayashi K; Sakamoto N; Matsuoka M; Nozaka T; Misumi Y; Matsumoto T; Miura N; Furumoto Y; Asano T; Horiuchi T; Fujiki K
    Clin J Gastroenterol; 2020 Feb; 13(1):17-21. PubMed ID: 31352645
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-RT) for locally advanced esophageal squamous cell carcinoma.
    Sasaki K; Uchikado Y; Omoto I; Arigami T; Osako Y; Noda M; Okumura H; Maemura K; Higashi R; Yoshiura T; Natsugoe S
    Cancer Chemother Pharmacol; 2019 Mar; 83(3):581-587. PubMed ID: 30623230
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Comparison between docetaxel plus cisplatin and cisplatin plus fluorouracil in the neoadjuvant chemoradiotherapy for local advanced esophageal squamous cell carcinoma].
    Wu S; Chen MY; Luo JC; Wei L; Chen Z
    Zhonghua Zhong Liu Za Zhi; 2012 Nov; 34(11):873-6. PubMed ID: 23291141
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Salvage treatment for lymph node recurrence after radical resection of esophageal squamous cell carcinoma.
    Chen J; Yin W; Yao H; Gu W
    Radiat Oncol; 2019 Sep; 14(1):169. PubMed ID: 31533757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant chemoradiotherapy with cisplatin plus vinorelbine versus cisplatin plus fluorouracil for esophageal squamous cell carcinoma: A matched case-control study.
    Liu SL; Yang H; Zhang P; Zhang L; Zhao L; Luo LL; Fu JH; Liu MZ; Xi M
    Radiother Oncol; 2015 Aug; 116(2):262-8. PubMed ID: 26243678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison between surgery and definitive chemoradiotherapy for patients with resectable esophageal squamous cell carcinoma: a propensity score analysis.
    Nomura M; Oze I; Kodaira T; Abe T; Komori A; Narita Y; Masuishi T; Taniguchi H; Kadowaki S; Ura T; Andoh M; Tachibana H; Uemura N; Tajika M; Niwa Y; Muto M; Muro K
    Int J Clin Oncol; 2016 Oct; 21(5):890-898. PubMed ID: 26980212
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enteral nutrition and quality of life in patients undergoing chemoradiotherapy for esophageal carcinoma: a comparison of nasogastric tube, esophageal stent, and ostomy tube feeding.
    Yu FJ; Shih HY; Wu CY; Chuang YS; Lee JY; Li HP; Fang PT; Tsai DL; Chou SH; Wu IC
    Gastrointest Endosc; 2018 Jul; 88(1):21-31.e4. PubMed ID: 29225081
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relief of dysphagia during neoadjuvant treatment for cancer of the esophagus or gastroesophageal junction.
    Sunde B; Ericson J; Kumagai K; Lundell L; Tsai JA; Lindblad M; Rouvelas I; Friesland S; Wang N; Nilsson M
    Dis Esophagus; 2016 Jul; 29(5):442-7. PubMed ID: 25809837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant chemoradiotherapy with concurrent cisplatin/5-fluorouracil is associated with increased pathologic complete response and improved survival compared to carboplatin/paclitaxel in patients with locally advanced esophageal cancer.
    Haisley KR; Hart KD; Nabavizadeh N; Bensch KG; Vaccaro GM; Thomas CR; Schipper PH; Hunter JG; Dolan JP
    Dis Esophagus; 2017 Jul; 30(7):1-7. PubMed ID: 28475724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk factors for esophageal fistula in thoracic esophageal squamous cell carcinoma invading adjacent organs treated with definitive chemoradiotherapy: a monocentric case-control study.
    Kawakami T; Tsushima T; Omae K; Ogawa H; Shirasu H; Kito Y; Yoshida Y; Hamauchi S; Todaka A; Machida N; Yokota T; Yamazaki K; Fukutomi A; Onozawa Y; Yasui H
    BMC Cancer; 2018 May; 18(1):573. PubMed ID: 29776344
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A case of reversible encephalopathy syndrome caused by hyponatremia during neoadjuvant 5-FU+CDDP therapy for esophageal cancer].
    Kobayashi Y; Nozaki I; Hato S; Kobatake T; Ohta K; Kubo Y; Tanada M; Kurita A
    Gan To Kagaku Ryoho; 2013 Mar; 40(3):379-81. PubMed ID: 23507603
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of Dysphagia in Esophageal Adenocarcinoma Patients Undergoing Neoadjuvant Chemotherapy: Can Invasive Tube Feeding be Avoided?
    Cools-Lartigue J; Jones D; Spicer J; Zourikian T; Rousseau M; Eckert E; Alcindor T; Vanhuyse M; Asselah J; Ferri LE
    Ann Surg Oncol; 2015; 22(6):1858-65. PubMed ID: 25476030
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant irinotecan, cisplatin, and concurrent radiation therapy with celecoxib for patients with locally advanced esophageal cancer.
    Cleary JM; Mamon HJ; Szymonifka J; Bueno R; Choi N; Donahue DM; Fidias PM; Gaissert HA; Jaklitsch MT; Kulke MH; Lynch TP; Mentzer SJ; Meyerhardt JA; Swanson RS; Wain J; Fuchs CS; Enzinger PC
    BMC Cancer; 2016 Jul; 16():468. PubMed ID: 27412386
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II feasibility study of preoperative concurrent chemoradiotherapy with cisplatin plus 5-fluorouracil and elective lymph node irradiation for clinical stage II/III esophageal squamous cell carcinoma.
    Hashimoto J; Kato K; Ito Y; Kojima T; Akimoto T; Daiko H; Hamamoto Y; Matsushita H; Katano S; Hara H; Tanaka Y; Saito Y; Nagashima K; Igaki H
    Int J Clin Oncol; 2019 Jan; 24(1):60-67. PubMed ID: 30109544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of concurrent chemoradiotherapy as a palliative treatment in stage IVB esophageal cancer patients with dysphagia.
    Ikeda E; Kojima T; Kaneko K; Minashi K; Onozawa M; Nihei K; Fuse N; Yano T; Yoshino T; Tahara M; Doi T; Ohtsu A
    Jpn J Clin Oncol; 2011 Aug; 41(8):964-72. PubMed ID: 21742654
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment-Related Lymphopenia Predicts Pathologic Complete Response and Recurrence in Esophageal Squamous Cell Carcinoma Undergoing Neoadjuvant Chemoradiotherapy.
    Li Q; Zhou S; Liu S; Liu S; Yang H; Zhao L; Liu M; Hu Y; Xi M
    Ann Surg Oncol; 2019 Sep; 26(9):2882-2889. PubMed ID: 31037433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A retrospective comparison of neoadjuvant chemoradiotherapy regimens for locally advanced esophageal cancer.
    Sanford NN; Catalano PJ; Enzinger PC; King BL; Bueno R; Martin NE; Hong TS; Wo JY; Mamon HJ
    Dis Esophagus; 2017 Jul; 30(7):1-8. PubMed ID: 28475728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of SPARC and TUBB3 as predictors for prognosis in esophageal squamous cell carcinoma receiving nab-paclitaxel plus cisplatin neoadjuvant chemotherapy: a prospective study.
    Gong L; Mao W; Chen Q; Jiang Y; Fan Y
    Cancer Chemother Pharmacol; 2019 Apr; 83(4):639-647. PubMed ID: 30643929
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment options for esophageal squamous cell carcinoma.
    Nakajima M; Kato H
    Expert Opin Pharmacother; 2013 Jul; 14(10):1345-54. PubMed ID: 23675862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term results of concurrent chemoradiotherapy with daily-low-dose continuous infusion of 5-fluorouracil and cisplatin (LDFP) for Stage I-II esophageal carcinoma.
    Kumabe A; Fukada J; Kota R; Koike N; Shiraishi Y; Seki S; Yoshida K; Kitagawa Y; Shigematsu N
    Dis Esophagus; 2018 Apr; 31(4):. PubMed ID: 29228166
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.